Taysha Gene Therapies, Inc. (TSHA)
5.07
+0.01
(+0.20%)
USD |
NASDAQ |
Sep 16, 16:00
5.075
0.00 (0.00%)
After-Hours: 20:00
Taysha Gene Therapies Price to Book Value : 4.259 for Sept. 16, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 16, 2026 | 4.259 |
| September 15, 2026 | 4.250 |
| September 14, 2026 | 4.208 |
| September 11, 2026 | 4.217 |
| September 10, 2026 | 4.334 |
| September 09, 2026 | 4.486 |
| September 08, 2026 | 4.603 |
| September 04, 2026 | 4.704 |
| September 03, 2026 | 4.679 |
| September 02, 2026 | 4.738 |
| September 01, 2026 | 4.788 |
| August 31, 2026 | 4.780 |
| August 28, 2026 | 4.847 |
| August 27, 2026 | 5.006 |
| August 26, 2026 | 5.057 |
| August 25, 2026 | 5.208 |
| August 24, 2026 | 5.015 |
| August 21, 2026 | 5.116 |
| August 20, 2026 | 5.132 |
| August 19, 2026 | 5.401 |
| August 18, 2026 | 5.200 |
| August 17, 2026 | 5.216 |
| August 14, 2026 | 4.998 |
| August 13, 2026 | 5.032 |
| August 12, 2026 | 5.380 |
| Date | Value |
|---|---|
| August 11, 2026 | 5.611 |
| August 10, 2026 | 5.351 |
| August 07, 2026 | 5.510 |
| August 06, 2026 | 5.326 |
| August 05, 2026 | 5.426 |
| August 04, 2026 | 5.208 |
| August 03, 2026 | 4.855 |
| July 31, 2026 | 4.922 |
| July 30, 2026 | 4.935 |
| July 29, 2026 | 4.712 |
| July 28, 2026 | 4.586 |
| July 27, 2026 | 4.654 |
| July 24, 2026 | 4.637 |
| July 23, 2026 | 4.897 |
| July 22, 2026 | 4.754 |
| July 21, 2026 | 4.763 |
| July 20, 2026 | 4.687 |
| July 17, 2026 | 5.006 |
| July 16, 2026 | 5.015 |
| July 15, 2026 | 5.200 |
| July 14, 2026 | 4.788 |
| July 13, 2026 | 4.519 |
| July 10, 2026 | 5.326 |
| July 09, 2026 | 5.519 |
| July 08, 2026 | 5.452 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Altimmune, Inc. | 1.329 |
| Protalix Biotherapeutics, Inc. | 3.024 |
| Humacyte, Inc. | 5.065 |
| Agenus, Inc. | -- |
| Amgen, Inc. | 17.41 |
Price to Book Value Related Metrics
| PS Ratio | 317.52 |
| PEG Ratio | -0.5561 |
| Price | 5.07 |
| Earnings Yield | -8.53% |
| Market Cap | 1.649B |
| PEGY Ratio | -0.5561 |